eprintid: 10206201
rev_number: 8
eprint_status: archive
userid: 699
dir: disk0/10/20/62/01
datestamp: 2025-03-18 09:56:07
lastmod: 2025-03-18 09:56:07
status_changed: 2025-03-18 09:56:07
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Ismail, Muhammad Azam
creators_name: Tittle, Victoria
creators_name: Jones, Rachael
creators_name: Loftus, Hannah
creators_name: Girometti, Nicolo
creators_name: Dosekun, Olamide
creators_name: Stegmann, Katrina
creators_name: Pool, Erica
creators_name: Tariq, Shema
creators_name: Nakamura, Anna
creators_name: Tyler, Stephanie
creators_name: Coleman, Harry
creators_name: Teh, Yee Suh
creators_name: Boffito, Marta
title: Therapeutic drug monitoring of tenofovir disoproxil and emtricitabine in oral HIV pre-exposure prophylaxis (PrEP) users who have undergone gastrointestinal surgery
ispublished: pub
divisions: UCL
divisions: B02
divisions: D01
keywords: Pre-exposure prophylaxis, therapeutic drug monitoring, HIV, gastrointestinal surgery
note: This version is the author-accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
abstract: Objectives:
Oral HIV pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV, but its efficacy depends on adequate absorption of drug, which may decrease following gastrointestinal surgery.//
Methods:
Clinicians across eight Genito-urinary Medicine clinics in the United Kingdom submitted data on PrEP users with history of gastrointestinal surgery who were referred to a national complex PrEP multi-disciplinary team between June 2021 and April 2023. Anonymised data were submitted on demographics, surgical history, PrEP regimen, and results of therapeutic drug monitoring (TDM) and HIV screening tests. Descriptive analyses were performed in SPSS version 29.//
Results:
Nine cases described cis-gender men-who-have-sex-with-men (MSM) with median age of 47.4 years (IQR = 43 – 56.5) taking tenofovir disoproxil (TDF)/emtricitabine (FTC) daily (n = 8) or event-based (n = 1) as PrEP. Median time between PrEP initiation and TDM was 53 days (IQR = 8.5–1705). The mean (±SD) trough concentration of tenofovir (TFV) and FTC were 90.2 ± 27.7 ng/mL and 76.0 ± 45.9 ng/mL, respectively. All patients had a negative HIV test at follow-up.//
Conclusions:
Plasma trough concentrations of TFV observed in our cohort taking TDF/FTC were above the expected concentrations associated with PrEP efficacy as previously described in the literature, suggesting that PrEP can be safely given in this population, with TDM used for reassurance.
date: 2025-03
date_type: published
publisher: Royal Society of Medicine Press
official_url: https://doi.org/10.1177/09564624241298983
oa_status: green
full_text_type: other
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 2335073
doi: 10.1177/09564624241298983
medium: Print-Electronic
lyricists_name: Pool, Erica
lyricists_name: Tariq, Shema
lyricists_id: ERMPO69
lyricists_id: STARI14
actors_name: Tariq, Shema
actors_id: STARI14
actors_role: owner
full_text_status: public
publication: International Journal of STD and AIDS
volume: 36
number: 3
pagerange: 250-254
event_location: England
issn: 0956-4624
citation:        Ismail, Muhammad Azam;    Tittle, Victoria;    Jones, Rachael;    Loftus, Hannah;    Girometti, Nicolo;    Dosekun, Olamide;    Stegmann, Katrina;                             ... Boffito, Marta; + view all <#>        Ismail, Muhammad Azam;  Tittle, Victoria;  Jones, Rachael;  Loftus, Hannah;  Girometti, Nicolo;  Dosekun, Olamide;  Stegmann, Katrina;  Pool, Erica;  Tariq, Shema;  Nakamura, Anna;  Tyler, Stephanie;  Coleman, Harry;  Teh, Yee Suh;  Boffito, Marta;   - view fewer <#>    (2025)    Therapeutic drug monitoring of tenofovir disoproxil and emtricitabine in oral HIV pre-exposure prophylaxis (PrEP) users who have undergone gastrointestinal surgery.                   International Journal of STD and AIDS , 36  (3)   pp. 250-254.    10.1177/09564624241298983 <https://doi.org/10.1177/09564624241298983>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10206201/1/Main%20Body%20TDM%20Paper%20Revised%20v1.1.pdf